Correction: Narongkiatikhun et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. Vaccines 2023, 11, 175
- PMID: 37897029
- PMCID: PMC10611367
- DOI: 10.3390/vaccines11101538
Correction: Narongkiatikhun et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. Vaccines 2023, 11, 175
Abstract
The authors wish to make the following correction to this paper [...].
Erratum for
-
Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study.Vaccines (Basel). 2023 Mar 23;11(4):715. doi: 10.3390/vaccines11040715. Vaccines (Basel). 2023. PMID: 37112627 Free PMC article.
References
-
- Narongkiatikhun P., Noppakun K., Chaiwarith R., Winichakoon P., Vongsanim S., Suteeka Y., Pongsuwan K., Kusirisin P., Wongsarikan N., Fanhchaksai K., et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. Vaccines. 2023;11:715. doi: 10.3390/vaccines11040715. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
